Eli Lilly & Co. Third Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Eli Lilly & Co. (NYSE:LLY) will unveil its latest earnings on Thursday, October 20, 2011. Eli Lilly develops and manufactures pharmaceutical products as well as animal health products.

Eli Lilly & Co. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.13 per share, a decline of 6.6% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.09. Between one and three months ago, the average estimate moved up. It has been unchanged at $1.13 during the last month. Analysts are projecting profit to rise by 8.6% versus last year to $4.33.

Past Earnings Performance: The company missed estimates last quarter after beating forecasts in the prior two. In the second quarter, the company reported profit of $1.18 per share versus a mean estimate of net income of $1.19 per share. In the first quarter, the company beat estimates by 7 cents.

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 6.7% in revenue from the year-earlier quarter to $6.03 billion.

Analyst Ratings: Analysts seem relatively indifferent about Eli Lilly & with 12 of 17 analysts surveyed maintaining a hold rating.

A Look Back: In the second quarter, profit fell 11.2% to $1.2 billion ($1.07 a share) from $1.35 billion ($1.22 a share) the year earlier, missing analyst expectations. Revenue rose 8.8% to $6.25 billion from $5.75 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 6.4% in the first quarter from the year earlier, climbed 4.3% in the fourth quarter of the last fiscal year from the year-ago quarter and 1.7% in the third quarter of the last fiscal year.

The company has seen net income fall in each of the last two quarters. Net income dropped 15.4% in the first quarter.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN), GlaxoSmithKline plc (NYSE:GSK), Alkermes, Inc. (NASDAQ:ALKS), Roche Holding Ltd. (RHHBY), Novartis AG (NYSE:NVS), and Abbott Laboratories (NYSE:ABT).

Stock Price Performance: During August 18, 2011 to October 14, 2011, the stock price had risen $3.28 (9.4%) from $35.01 to $38.29. The stock price saw one of its best stretches over the last year between April 29, 2011 and May 16, 2011 when shares rose for 12-straight days, rising 7.1% (+$2.57) over that span. It saw one of its worst periods between November 9, 2010 and November 17, 2010 when shares fell for seven-straight days, falling 2.5% (-85 cents) over that span. Shares are up $4.65 (+13.8%) year to date.

(Source: Xignite Financials)

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.

 

More from The Cheat Sheet